With a deeper understanding of these mechanisms, the DARPP-32/CXCR4/CXCL-12 complex axis should be considered a type of targeted therapy to inhibit tumor progression and improve outcomes in patients with gastric cancer. Here, CXCR4 is linked to gastric cancer.